DBV Technologies to Participate in Multiple September Investor Conferences
02 Septembre 2020 - 10:30PM
Montrouge, France, September 2, 2020
DBV Technologies to Participate in Multiple
September Investor Conferences
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced its participation in the
following virtual investor conferences in September:
Citi’s 15th
Annual BioPharma Virtual Conference, September
9-10.DBV’s management team will
participate in virtual investor meetings at the conference.
Goldman Sachs
10th Annual Biotech
Symposium, September 11. DBV’s management team will
participate in virtual investor meetings at the conference on
Friday, September 11.
H. C. Wainwright 22nd Annual Global
Investment Conference, September 14-16.Daniel Tassé, Chief
Executive Officer, will participate in a fireside chat at the
conference on Tuesday, September 15 at 10:00 AM ET.
Morgan Stanley 18th Annual Global
Healthcare Conference, September 14-18.Daniel Tassé, Chief
Executive Officer, will participate in a fireside chat at the
conference on Wednesday, September 16 at 8:45 AM ET.
A live webcast of each of the presentations at
the H. C. Wainwright 22nd Annual Global Investment Conference and
the Morgan Stanley 18th Annual Global Healthcare Conference will be
available on the Investors & Media section of the Company’s
website: https://www.dbv-technologies.com/investor-relations/. A
replay of each presentation will also be available on DBV’s website
after the respective event.
About DBV Technologies DBV
Technologies is developing Viaskin®, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut (DBV712). DBV Technologies has global headquarters in
Montrouge, France and offices in Bagneux, France, and North
American operations in Summit, NJ and New York, NY. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345), part of the SBF120 index, and the
Company’s ADSs (each representing one-half of one ordinary share)
are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Investor
Relations Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024